Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Conner: Tell us about the new recommendations for the pneumonia vaccine.

This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Pneumococcal disease remains a major global health challenge ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs ... it as the first candidate with over 20 serotypes in this trial phase for ...

South Korean pharmaceutical company SK Bioscience said Monday that it has joined forces with French drugmaker Sanofi to ...

is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have entered into a new ...